Literature DB >> 28857155

Prevalent somatic BRCA1 mutations shape clinically relevant genomic patterns of nasopharyngeal carcinoma in Southeast Europe.

George Fountzilas1,2, Amanda Psyrri3, Eleni Giannoulatou4,5, Ioannis Tikas1, Kyriaki Manousou6, Dimitra Rontogianni7, Elisabeta Ciuleanu8, Tudor Ciuleanu9, Liliana Resiga10, Thomas Zaramboukas11, Kyriaki Papadopoulou1, Mattheos Bobos1, Sofia Chrisafi1, Eleftheria Tsolaki1, Konstantinos Markou12, Evangelos Giotakis13, Angelos Koutras14, Elsa Psoma15, Anna Kalogera-Fountzila15, Maria Skondra16, Christina Bamia17, Dimitrios Pectasides16, Vassiliki Kotoula1,11.   

Abstract

Genomic patterns of nasopharyngeal carcinomas (NPCs) have as yet been studied in Southeast Asian (SEA) patients. Here, we investigated genomic patterns of locally advanced NPC Southeast European (SEE) patients treated with chemoradiotherapy. We examined 126 tumors (89% EBV positive) from Greek and Romanian NPC patients with massively parallel sequencing. Paired tumor-cell-rich (TC) and infiltrating-lymphocyte-rich (TILs) samples were available in 19 and paired tumor-germline samples in 68 cases. Top mutated genes were BRCA1 (54% of all tumors); BRCA2 (29%); TP53 (22%); KRAS (18%). Based on the presence and number of mutations and mutated genes, NPC were classified as stable (no mutations, n = 27); unstable (>7 genes with multiple mutations, all BRCA1 positive, n = 21); and of intermediate stability (1-7 singly mutated genes, n = 78). BRCA1 p.Q563* was present in 59 tumors (48%), more frequently from Romanian patients (p < 0.001). No pathogenic germline mutations were identified. NPC exhibited APOBEC3A/B and nucleotide-excision-repair-related mutational signatures. As compared to TC, TILs demonstrated few shared and a higher number of low frequency private mutations (p < 0.001). In multivariate analysis models for progression-free survival, EBV positivity was a favorable prognosticator in stable tumors; BRCA1 mutations were unfavorable only in tumors of intermediate stability. In conclusion, other than described for SEA NPC, somatic BRCA1 mutations were common in SEE NPC; these were shared between TC and TILs, and appeared to affect patient outcome according to tumor genomic stability status. Along with the identified mutational signatures, these novel data may be helpful for designing new treatments for locally advanced NPC.
© 2017 UICC.

Entities:  

Keywords:  APOBEC3A/B; BRCA1; BRCA2; nasopharyngeal carcinoma; next generation sequencing; somatic mutation; tumor infiltrating lymphocytes

Mesh:

Substances:

Year:  2017        PMID: 28857155     DOI: 10.1002/ijc.31023

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  3 in total

1.  Downregulation of ribophorin II suppresses tumor growth, migration, and invasion of nasopharyngeal carcinoma.

Authors:  Feilong Hong; Yong Li; Haifeng Ni; Jing Li
Journal:  Onco Targets Ther       Date:  2018-06-15       Impact factor: 4.147

2.  Multiscale Local Enhancement Deep Convolutional Networks for the Automated 3D Segmentation of Gross Tumor Volumes in Nasopharyngeal Carcinoma: A Multi-Institutional Dataset Study.

Authors:  Geng Yang; Zhenhui Dai; Yiwen Zhang; Lin Zhu; Junwen Tan; Zefeiyun Chen; Bailin Zhang; Chunya Cai; Qiang He; Fei Li; Xuetao Wang; Wei Yang
Journal:  Front Oncol       Date:  2022-03-18       Impact factor: 6.244

3.  EBV-encoded miRNAs can sensitize nasopharyngeal carcinoma to chemotherapeutic drugs by targeting BRCA1.

Authors:  Raymond Wai-Ming Lung; Joanna Hung-Man Tong; Lok-Man Ip; Ka-Hei Lam; Anthony Wing-Hung Chan; Wing-Po Chak; Lau-Ying Chung; Walter Wai Yeung; Pok-Man Hau; Shuk-Ling Chau; Sai-Wah Tsao; Kin-Mang Lau; Kwok-Wai Lo; Ka-Fai To
Journal:  J Cell Mol Med       Date:  2020-10-19       Impact factor: 5.295

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.